Crinetics Pharmaceuticals (CRNX) has provided an update.
Crinetics Pharmaceuticals, Inc. has announced encouraging preliminary results for its new oral medication, atumelnant, showing potential in treating ACTH-dependent Cushing’s syndrome and congenital adrenal hyperplasia. This news, alongside positive findings from their acromegaly treatment paltusotine, was shared at the prestigious ENDO 2024 conference. Investors and interested parties can access the details through the company’s website and an upcoming webcast, promising advancements in Crinetics’ clinical programs.
See more insights into CRNX stock on TipRanks’ Stock Analysis page.
